Pulmonary hypertension in diffuse parenchymal lung diseases - is there any benefit of PAH-specific therapy?
Sign Up to like & getrecommendations! Published in 2017 at "Advances in respiratory medicine"
DOI: 10.5603/arm.2017.0036
Abstract: Pulmonary hypertension (PH) is diagnosed in 40-50% of the patients with end-stage diffuse parenchymal lung diseases (DPLD), and it is associated with significant worsening of life expectancy. Latest ERS/ESC guidelines recommend best available treatment of… read more here.
Keywords: therapy; pulmonary hypertension; specific therapy; pah specific ... See more keywords